drugset / Trial / NCT04672291

Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults

NCT04672291

Phase 1 Completed 43 enrolled Oncovir, Inc. University of Calgary · collab
RandomizedSequentialQuadruple-blindPrevention

Summary

This is a randomized (4:1) Phase 1 b safety trial in adults who have completed their full COVID-19 vaccination schedule at least 30 days prior to study entry.

Timeline

Start
2021-07-21
Primary completion
2023-04-01
Completion
2023-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified

Indications